Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Share-based Compensation for 8 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 12.46% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $205000.0 (down 90.95% YoY), while the FY2025 annual figure was $63.4 million, down 7.31% from the prior year.
• Share-based Compensation grew to $16.0 million in Q1 2026 per KYMR's latest filing, from -$45.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $73.5 million in Q3 2025 and bottomed at -$45.5 million in Q4 2025.
• Historically, Share-based Compensation has averaged $9.0 million across 5 years, with a median of $11.4 million in 2023.
• Annual changes were most pronounced in 2024 — Share-based Compensation sank 478.17% — and 2025, when it surged 393.16%.
• Kymera Therapeutics' Share-based Compensation stood at $9.1 million in 2022, then gained by 20.07% to $10.9 million in 2023, then tumbled by 478.17% to -$41.2 million in 2024, then fell by 10.28% to -$45.5 million in 2025, then surged by 135.22% to $16.0 million in 2026.
• Business Quant data shows KYMR's Share-based Compensation at $16.0 million in Q1 2026, -$45.5 million in Q4 2025, and $73.5 million in Q3 2025.